ABBVIE INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 160.3 USD | +0.45% |
|
-4.46% | +3.50% |
| 05:26pm | BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating | MT |
| 02:52pm | Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196 | MT |
Financials (USD)
| Sales 2024 * | 54.99B | Sales 2025 * | 57.8B | Capitalization | 283B |
|---|---|---|---|---|---|
| Net income 2024 * | 7.78B | Net income 2025 * | 11.03B | EV / Sales 2024 * | 6.09 x |
| Net Debt 2024 * | 52.07B | Net Debt 2025 * | 44.73B | EV / Sales 2025 * | 5.66 x |
| P/E ratio 2024 * |
31.2
x | P/E ratio 2025 * |
24.3
x | Employees | 50,000 |
| Yield 2024 * |
3.88% | Yield 2025 * |
4.07% | Free-Float | 96.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on AbbVie Inc.
More recommendations
More press releases
| 1 day | +0.58% | ||
| 1 week | -4.78% | ||
| Current month | -12.21% | ||
| 1 month | -11.56% | ||
| 3 months | -2.46% | ||
| 6 months | +12.67% | ||
| Current year | +3.16% |
1 week
157.65
170.37
1 month
157.65181.90
Current year
154.77182.89
1 year
130.96182.89
3 years
105.56182.89
5 years
62.55182.89
10 years
45.45182.89
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 12-12-31 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 12-12-31 |
Robert Michael
PSD | President | 53 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 12-12-31 |
Edward Rapp
BRD | Director/Board Member | 66 | 12-12-31 |
| Director/Board Member | 70 | 12-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.12% | 6 M€ | 0.00% | - | |
| 6.85% | 18 M€ | +3.79% | - | |
| 6.26% | 13 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 160.3 | +0.43% | 2 791 530 |
| 24-04-26 | 159.6 | -4.58% | 10,721,740 |
| 24-04-25 | 167.3 | -0.30% | 5,503,656 |
| 24-04-24 | 167.8 | -1.03% | 4,074,765 |
| 24-04-23 | 169.5 | +0.98% | 4,084,105 |
Delayed Quote Nyse, April 29, 2024 at 12:00 pm EDT
More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
2024-05-03
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
159.6
USD
Average target price
183
USD
Spread / Average Target
+14.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.16% | 283B | |
| +25.64% | 661B | |
| +26.74% | 566B | |
| -6.54% | 352B | |
| +19.95% | 332B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -5.15% | 145B | |
| -10.63% | 144B |
- Stock Market
- Equities
- ABBV Stock
